Voting rights and capital

Hikma Pharmaceuticals Plc
21 December 2006




             Hikma Pharmaceuticals PLC - Voting Rights and Capital

LONDON, 21 December 2006 - In conformity with the Transparency Directive's
transitional provision 6 we would like to notify the market of the following:

Hikma Pharmaceuticals PLC's capital consists of 168,164,207 ordinary shares with
voting rights.

The above figure (168,164,207) may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC
under the FSA's Disclosure and Transparency Rules.

                                    - ENDS -
Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal                                    [phone]
Investor Relations Director

Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed         [phone]

About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange